Hypertrophic cardiomyopathy with coronary artery disease

Hypertrophic Cardiomyopathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hypertrophic Cardiomyopathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hypertrophic cardiomyopathy with coronary artery disease On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hypertrophic cardiomyopathy with coronary artery disease
CDC on Hypertrophic cardiomyopathy with coronary artery disease
Hypertrophic cardiomyopathy with coronary artery disease in the news
Blogs on Hypertrophic cardiomyopathy with coronary artery disease
Directions to Hospitals Treating Hypertrophic cardiomyopathy
Risk calculators and risk factors for Hypertrophic cardiomyopathy with coronary artery disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Concomitant Coronary Disease

2011 ACCF/AHA Guideline Recommendations: Detection of Concomitant Coronary Disease(DO NOT EDIT)

“

Class I 1. Coronary arteriography (invasive or computed tomographic imaging) is indicated in patients with HCM with chest discomfort who have an intermediate to high likelihood of CAD when the identification of concomitant CAD will change management strategies. Class III (Harm) 1. Routine SPECT MPI or stress echocardiography is not indicated for detection of “silent” CAD-related ischemia in patients with HCM who are asymptomatic. 2. Assessment for the presence of blunted flow reserve (microvascular ischemia) using quantitative myocardial blood flow measurements by PET is not indicated for the assessment of prognosis in patients with HCM. Class IIa

”